VIROPTIC Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Viroptic, and what generic alternatives are available?
Viroptic is a drug marketed by Monarch Pharms and is included in one NDA.
The generic ingredient in VIROPTIC is trifluridine. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the trifluridine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Viroptic
A generic version of VIROPTIC was approved as trifluridine by SANDOZ on October 6th, 1995.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for VIROPTIC?
- What are the global sales for VIROPTIC?
- What is Average Wholesale Price for VIROPTIC?
Summary for VIROPTIC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 72 |
| Clinical Trials: | 1 |
| Patent Applications: | 4,837 |
| Drug Prices: | Drug price information for VIROPTIC |
| DailyMed Link: | VIROPTIC at DailyMed |
Recent Clinical Trials for VIROPTIC
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Eye Institute (NEI) | Phase 2 |
US Patents and Regulatory Information for VIROPTIC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Monarch Pharms | VIROPTIC | trifluridine | SOLUTION/DROPS;OPHTHALMIC | 018299-001 | Approved Prior to Jan 1, 1982 | AT | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
